The Living Guidelines: UA/NSTEMI Recommendations for Hormone Therapy Suggest Revisions to the CLASS III Guidelines

Any recommendations found on these pages are for education use only. WikiDoc is not a substitute for a licensed healthcare provider. Please see the disclaimers page for important information regarding limitations of the information found here. In suggesting edits to the guidelines, WikiDoc suggests that the following classification scheme be used. Read more about the classification scheme used by the ACC / AHA Guidelines Committee here.

Instructions on How to Edit the Guidelines:
 * Log in
 * Click on "Edit"
 * Type in changes to guidelines
 * Click "Save page" at the bottom of the page

Class III Guidelines

 * 1) Hormone therapy with estrogen plus progestin, or estrogen alone, should not be given de novo to postmenopausal women after UA / NSTEMI for secondary prevention of coronary events. (Level of Evidence: A)
 * 2) Postmenopausal women who are already taking estrogen plus progestin, or estrogen alone, at the time of UA / NSTEMI in general should not continue hormone therapy. However, women who are more than 1 to 2 years past the initiation of hormone therapy who wish to continue such therapy for another compelling indication should weigh the risks and benefits, recognizing the greater risk of cardiovascular events and breast cancer (combination therapy) or stroke (estrogen). Hormone therapy should not be continued while patients are on bed rest in the hospital. (Level of Evidence: B)